Evidence map›Paper›PMID 39216830›Full record

ArticleThe Journal of infection2024

Children with hemoglobin C or S trait have low serologic responses to a subset of malaria variant surface antigens.

Rachel D Bailey, Jonathan G Lawton, Amadou Niangaly, Emily M Stucke, Jason A Bailey, Andrea A Berry, Amed Ouattara, Drissa Coulibaly, Kirsten E Lyke, Matthew B Laurens and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Rachel D BaileyMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: rbailey@som.umaryland.edu.
Jonathan G LawtonMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: JLawton@som.umaryland.edu.
Amadou NiangalyMalaria Research and Training Center, University Science, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. Electronic address: niangaly@mrtcbko.org.
Emily M StuckeMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: Emily.Stucke@umaryland.edu.
Jason A BaileyMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: JBailey@som.umaryland.edu.
Andrea A BerryMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: aberry@som.umaryland.edu.
Amed OuattaraMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: amouattara@som.umaryland.edu.
Drissa CoulibalyMalaria Research and Training Center, University Science, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. Electronic address: coulibalyd@icermali.org.
Kirsten E LykeMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: klyke@som.umaryland.edu.
Matthew B LaurensMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: MLaurens@som.umaryland.edu.
Albert E ZhouMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: Albert.Zhou@som.umaryland.edu.
Jozelyn PabloDivision of Infectious Diseases, Department of Medicine, University of California, 101 The City Drive, Orange, CA 92868, United States of America. Electronic address: jozelynp@gmail.com.
Algis JasinskasDivision of Infectious Diseases, Department of Medicine, University of California, 101 The City Drive, Orange, CA 92868, United States of America. Electronic address: ajasinsk@uci.edu.
Rie NakajimaDivision of Infectious Diseases, Department of Medicine, University of California, 101 The City Drive, Orange, CA 92868, United States of America. Electronic address: rie3@uci.edu.
Matthew AdamsMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: madams@som.umaryland.edu.
Shannon Takala-HarrisonMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: STakala@som.umaryland.edu.
Bourema KouribaMalaria Research and Training Center, University Science, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. Electronic address: kouriba@icermali.org.
Abdoulaye K KoneMalaria Research and Training Center, University Science, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. Electronic address: fankone@icermali.org.
Aldiouma GuindoMalaria Research and Training Center, University Science, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. Electronic address: aldguindo@icermali.org.
J Alexandra RoweCenter for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Charlotte Auerbach Road, Edinburgh EH9 3FL, United Kingdom. Electronic address: Alex.Rowe@ed.ac.uk.
Dapa A DialloMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: dadiallo@icermali.org.
Ogobara K DoumboMalaria Research and Training Center, University Science, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. Electronic address: okd@icermali.org.
Philip L FelgnerDivision of Infectious Diseases, Department of Medicine, University of California, 101 The City Drive, Orange, CA 92868, United States of America. Electronic address: pfelgner@uci.edu.
Christopher V PloweMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: plowe.chris@gmail.com.
Mahamadou A TheraMalaria Research and Training Center, University Science, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. Electronic address: mthera@icermali.org.
Mark A TravassosMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., HSF1 Room 480, Baltimore, MD 21201, United States of America. Electronic address: mtravass@som.umaryland.edu.

Funding

FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
Safety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2005 to 2009
$4.7M
Safety and efficacy of PfSPZ malaria vaccine in malaria-exposed adultsU01AI112367 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LAURENS, MATTHEW BRENT · 2015 to 2018
$2.8M
Variant surface antigens in cerebral malaria pathogenesisR01HL130750 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI FISHER, STEVEN A., HARRISON, SHANNON TAKALA · 2015 to 2018
$2.1M
Malaria variant surface antigen expression and vulnerability to disease in Malian children with Hemoglobin C traitR01HL146377 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI TRAVASSOS, MARK A · 2019 to 2023
$1.9M
Host vulnerability and parasite genetics in the development of cerebral malariaR01AI099628 · NIAID · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI THERA, MAHAMADOU ALI · 2014 to 2018
$625k
NHLBI NIH HHS R01 HL130750NHLBI NIH HHS R01 HL146377NIAID NIH HHS R01 AI099628NIAID NIH HHS T32 AI007524NIAID NIH HHS U01 AI112367NIAID NIH HHS U19 AI065683
6 · The paper itself

Abstract

Children with hemoglobin AC or AS have decreased susceptibility to clinical malaria. Parasite variant surface antigen (VSA) presentation on the surface of infected erythrocytes is altered in erythrocytes with hemoglobin C (Hb AC) or sickle trait (Hb AS) mutations in vitro. The protective role of incomplete or altered VSA presentation against clinical malaria in individuals with Hb AC or AS is unclear. Using a high-throughput protein microarray, we sought to use serological responses to VSAs as a measure of host exposure to VSAs among Malian children with Hb AC, Hb AS, or wildtype hemoglobin (Hb AA). In uncomplicated malaria, when compared to Hb AA children, Hb AC children had significantly lower serological responses to extracellular Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP1) domains but did not differ in responses to intracellular PfEMP1 domains and other VSAs, including members of the repetitive interspersed family (RIFIN) and subtelomeric variable open reading frame (STEVOR) family. Healthy children with Hb AC and Hb AS genotypes recognized fewer extracellular PfEMP1s compared to children with Hb AA, especially CD36-binding PfEMP1s. These reduced serologic responses may reflect reduced VSA presentation or lower parasite exposure in children with Hb AC or AS and provide insights into mechanisms of protection.

Indexed as

Antigens, ProtozoanHemoglobin CMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsSickle Cell TraitAdolescentAntibodies, ProtozoanAntigens, SurfaceChildChild, PreschoolFemaleHemoglobin, SickleHumansInfantMaleAntibodies, ProtozoanAntigens, ProtozoanAntigens, Surfaceerythrocyte membrane protein 1, Plasmodium falciparumHemoglobin CHemoglobin, SickleProtozoan ProteinsHemoglobin CHemoglobin SMalariaMaliPlasmodium falciparumProtein microarray

Identifiers

PMID39216830
PMCPMC11546587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.